Kieran McCafferty, MB BChir, MRCP, MDres - The Latest News on SGLT2 Inhibitors in Chronic Kidney Disease: Improving Outcomes With Early Intervention

episode

CME in Minutes: Education in Primary Care not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

The Ezra Klein Show: Jensen Huang Thinks A.I. Alarmism Has Gone Too Far 1h 50m · 25 Sep 2026 · Hard Fork

What If We’ve Missed the Beauty of Sex? | The Gospels | Matthew 5:27–32 16 min · 25 Sep 2026 · Ten Minute Bible Talks Devotional Bible Study

Trump’s Standoff With White House Reporters, and the Rise and Fall of ‘Pervert Glasses’ 14 min · 25 Sep 2026 · The Headlines

Green Demon - Classic 34 min · 25 Sep 2026 · Spooked

Trump Unleashes Secret Biblical Strategy Against Xi Jinping 22 min · 25 Sep 2026 · Politics By Faith w/Mike Slater

Big meet, little meat: the Trump-Xi summit 27 min · 25 Sep 2026 · Economist Podcasts

Report any issue

Source

Recorded23 Aug 2023

Publisherc.answersincme.com ↗

Handlerec:10296347

Show notes

Please visit answersincme.com/CKS860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in nephrology discusses when to use SGLT2 inhibitors in patients with chronic kidney disease. Upon completion of this activity, participants should be better able to: Describe the benefits of SGLT2 inhibitor use in the management of CKD; Define strategies for the early implementation of SGLT2 inhibitor therapy in CKD; and Identify appropriate patient populations for the early implementation of SGLT2 inhibitor therapy in CKD.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in